The Library
SELECT-D : anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism
Tools
Tools
Tools
Young, Annie M., Dunn, Janet A., Chapman, O., Grumett, J., Marshall, A. , Phillips, J. and Lokare, A. (2014) SELECT-D : anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology, 32 (15). doi:10.1200/jco.2014.32.15_suppl.tps9661
Research output not available from this repository, contact author.
Official URL: https://doi.org/10.1200/jco.2014.32.15_suppl.tps96...
Abstract
Background: Venous thromboembolism (VTE) in cancer patients is an important and increasingly frequent clinical problem. The impact of VTE on cancer patients can be considerable. Targeted selection by identifying patients with clinically relevant recurrent VTE may have wider health economic benefits whilst reducing patient risk through over-treatment. In the UK, dalteparin is the licensed anticoagulant for the extended treatment and prevention of recurrence of VTE in cancer patients and thus, the gold standard. Rivaroxaban is a highly selective direct Factor Xa inhibitor with oral bioavailability. Methods: Select-d is a prospective, randomised, open label, multicentre pilot trial comparing dalteparin (200 IU/kg daily subcutaneously for 1 month and 150 IU/kg months 2-6); and rivaroxaban (15 mg orally twice daily for 3 weeks and 20 mg once daily for 6 months in total) for cancer patients with VTE, with a second placebo-controlled randomisation (rivaroxaban vs placebo) comparing the duration of therapy (6 vs 12 months) in residual vein thrombosis (RVT) positive patients. 70% of patients are estimated to be RVT positive after initial treatment. 530 patients are being recruited toprovide reliable estimates of the primary outcome (VTE recurrence rates) to within the 95% confidence interval of 8% assuming VTE rates are 10% at six months. Secondary objectives include safety, acceptability, biomarker identification and health economics. The trial will recruit for two years with a minimum of one year follow up. Results will support optimal treatment for this key patient group. The independent TSC and DSMC fully support this important trial. At least 40 UK centres will participate in the trial. As of 1stFebruary 2014, 23 patients have been recruited from 24 open UK sites. Select-d is amongst the first randomised trials of the new oral anticoagulants in patients with cancer, following recent recommendations from the UK National Institute of Health and Care Excellence.(http://guidance.nice.org.uk/CG144, http://guidance.nice.org.uk/TA261, http://publications.nice.org.uk/quality-standard-for-diagnosis-and-management-of-venous-thromboembolic-diseases-qs29). Clinical trial information: 86712308.
| Item Type: | Journal Item | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | ||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
||||
| Journal or Publication Title: | Journal of Clinical Oncology | ||||
| Publisher: | American Society of Clinical Oncology | ||||
| ISSN: | 0732-183X | ||||
| Official Date: | 20 May 2014 | ||||
| Dates: |
|
||||
| Volume: | 32 | ||||
| Number: | 15 | ||||
| DOI: | 10.1200/jco.2014.32.15_suppl.tps9661 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Open Access | ||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
